Bharat Parenterals sees promoter Desai Shares increase stake to 39.64% with 900‑share purchase

What Bharat Parenterals announced

On 16 June 2026, Bharat Parenterals Limited filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing records that Desai Shares & Stock Private Limited, identified as a promoter of the target company, increased its shareholding in Bharat Parenterals through an open‑market purchase.

"Desai Shares & Stock Pvt Ltd acquired 900 equity shares of Bharat Parenterals between 03‑15 June 2026, raising its total holding to 27,32,436 shares (39.64% of voting capital)."

The filing was submitted to BSE (script code 541096) and copies were also sent to the company’s audit and secretarial committees.

Details of the acquisition

The acquirer, Desai Shares & Stock Pvt Ltd, already owned 27,31,536 voting‑right shares before the transaction, which represented 39.63% of the total share and voting capital of Bharat Parenterals. Between 3 June and 15 June 2026, the promoter purchased an additional 900 equity shares on the open market. This incremental purchase increased its stake by a marginal 0.013% of the total voting capital, bringing the post‑acquisition holding to 27,32,436 shares, or 39.64% of the total.

The total equity share capital of Bharat Parenterals remains unchanged at 68,91,963 shares of Rs 10 each, amounting to a nominal capital of Rs 6,89,19,630. No new shares were issued, and there were no convertible securities, warrants, or other instruments involved in the transaction.

Shareholding pattern after the purchase

The filing confirms that the acquirer belongs to the promoter group of Bharat Parenterals, satisfying the regulatory definition of a promoter under the SEBI SAST framework. No encumbrances, pledges, or liens were reported on the newly acquired shares.

Key facts at a glance

Why this matters for investors

The disclosure is a statutory requirement under SEBI’s SAST regulations, which aim to provide transparency when promoters or persons acting in concert acquire additional stakes. For shareholders, the filing confirms that the promoter’s shareholding has marginally increased, signalling continued confidence but also a slight consolidation of voting power. Since the acquisition was executed via open‑market purchases, there is no dilution of existing shareholders’ equity. However, the increase in promoter ownership may affect future board composition and strategic decisions, as promoters typically have greater influence over corporate governance.

Investors should note that the filing does not disclose the purchase price or any financing arrangements for the 900 shares. Consequently, the financial impact on the promoter’s cash position cannot be assessed from this document alone.

Conclusion

Bharat Parenterals’ regulator‑mandated filing on 16 June 2026 records that Desai Shares & Stock Pvt Ltd, a promoter, bought 900 additional equity shares in the open market, raising its stake from 39.63% to 39.64% of the total voting capital. The transaction does not alter the company’s share capital or dilute existing shareholders. The filing satisfies SEBI’s disclosure requirements, and no further regulatory approvals are indicated as pending.